3.8 Guanfacine for the Treatment of ADHD in Children and Adolescents With Down Syndrome: A Retrospective Chart Review Study

Abstract

ADHD affects up to 45% of children and adolescents with Down syndrome (DS). No randomized controlled trials on ADHD treatment in DS have been published. One small, prospective open-label trial of guanfacine in a sample of 23 children with DS suggests some benefit for irritability and hyperactivity. Current knowledge of ADHD treatments in the general population may or may not be applicable to persons with DS. Our objective was to characterize the effectiveness, tolerability, and safety of guanfacine treatment for ADHD in a small sample of youths with DS.